Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, Yonese J, Hashine K, Masumori N, Arai G, Saito S, Shinohara M, Shimizu N, Yamauchi A, Satoh T, Tochigi T, Kobayashi M, Fujimoto H, Kakimoto KI, Fukui I, Tsukamoto T, Nozaki M, Karasawa K, Hasumi M, Ohtani M, Ishiyama H, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Naito S, Yamanaka H; National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators. Yokomizo A, et al. Among authors: nishimura k. Cancer Med. 2021 May;10(10):3240-3248. doi: 10.1002/cam4.3895. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932114 Free PMC article. Clinical Trial.
[Therapy for hormone-refractory prostate cancer].
Nishimura K, Takahara S, Nonomura N, Okuyama A. Nishimura K, et al. Nihon Rinsho. 2002 Dec;60 Suppl 11:266-71. Nihon Rinsho. 2002. PMID: 12599583 Review. Japanese. No abstract available.
Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
Yoshida T, Matsuzaki K, Kobayashi Y, Takeda K, Nakayama M, Arai Y, Kakimoto K, Nishimura K. Yoshida T, et al. Among authors: nishimura k. Int Urol Nephrol. 2012 Apr;44(2):479-85. doi: 10.1007/s11255-011-0044-5. Epub 2011 Aug 6. Int Urol Nephrol. 2012. PMID: 21822599
STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S; Japan Immunotherapy SNPs-Study Group for Kidney Cancer. Eto M, et al. Among authors: nishimura k. Eur Urol. 2013 Apr;63(4):745-52. doi: 10.1016/j.eururo.2012.09.052. Epub 2012 Sep 28. Eur Urol. 2013. PMID: 23063454 Clinical Trial.
4,112 results